Drug Type Small molecule drug |
Synonyms (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, Cefmenoxime, Cefmenoxime hydrochloride (JP17/USP) + [11] |
Target |
Mechanism PBPs inhibitors(Bacterial penicillin-binding protein inhibitors), Cell wall inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (01 Feb 1983), |
Regulation- |
Molecular FormulaC32H35ClN18O10S6 |
InChIKeyMPTNDTIREFCQLK-UNVJPQNDSA-N |
CAS Registry75738-58-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01739 | Cefmenoxime Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Otitis Externa | JP | 10 Jul 1996 | |
Otitis Media | JP | 10 Jul 1996 | |
Sinusitis | JP | 10 Jul 1996 | |
Bacterial Infections | US | 30 Dec 1987 | |
Infectious Diseases | JP | Teva Takeda Pharma Ltd.Startup | 01 Feb 1983 |